Abstract
Metabotropic glutamate (mGlu) receptors are G protein-coupled receptors expressed primarily on neurons and glial cells modulating the effects of glutamatergic neurotransmission. The pharmacological manipulation of these receptors has been postulated to be valuable in the management of some neurological disorders.
Accordingly, the targeting of mGlu 5 receptors as a therapeutic approach for Parkinson's disease (PD) has been proposed, especially to manage the adverse symptoms associated to chronic treatment with classical PD drugs. Thus, the specific pharmacological blocking of mGlu 5 receptors constitutes one of the most attractive non-dopaminergicbased strategies for PD management in general and for the L-DOPA-induced diskynesia (LID) in particular. Overall, we provide here an update of the current state of the art of these mGlu 5 receptor-based approaches that are under clinical study as agents devoted to alleviate PD symptoms.
described, namely the mGlu 5a and mGlu 5b receptors, which differ in that mGlu 5b receptor has a 33-amino acid insert in the intracellular C-terminal domain [11] .
However, no functional differences have been reported between these two variants, although it has been postulated that alternative mGlu 5 receptor splicing may contribute to regulatory mechanisms for tissue-and context-specific expression of the mGlu 5 receptor gene [12] . Interestingly, mGlu 5 receptors are highly expressed within the CNS, thus they have been found in cerebral cortex (i.e. granule cells), hippocampus (i.e. dentate gyrus and pyramidal neurons of the CA1-3 area), olfactory bulb, lateral septum, striatum, nucleus accumbens and inferior colliculus [13] . At the subcellular level, mGlu 5 receptors have been mostly found in neuronal postsynaptic elements, showing a perisynaptic and extrasynaptic distribution [14] . Thus, activation of postsynaptic mGlu 5 receptors may regulate ion channels functioning and increase the excitability of several types of neurons [15] . In addition, putative presynaptic mGlu 5 autoreceptors have also been found, for instance in mouse cortical nerve endings [16] , to facilitate glutamate exocytosis. On the other hand, group I mGlu receptors have been shown to be specifically involved in corticostriatal synaptic plasticity [17] . For instance, activation of mGlu 1 receptor is required for the induction of corticostriatal long-term depression (LTD) [18] [19] [20] , a fact that is linked to the receptor's ability to modulate intracellular calcium concentration [21] . Or, it has also been shown that both mGlu 1 and mGlu 5 receptors mediate in corticostriatal long-term potentiation (LTP), since simultaneous blockade of both receptors abolishes this phenomenon [22] .
Overall, mGlu receptors play a key role in CNS functioning, thus when the glutamatergic system is deregulated, as it occurs in excitotoxic brain conditions associated to some neurodegenerative diseases, the pharmacological manipulation of these receptors (i.e. blockade of group I or activation of group II and III mGlu receptors) has been postulated to exert beneficial effects. Accordingly, in the recent years it has been considered the usefulness of mGlu 5 receptor blockade as a nondopaminergic therapeutic approach of PD, specially to manage the adverse symtoms associated to prolonged dopaminergic-based therapy (i.e. dyskinesia and motor fluctuations).
GLUTAMATERGIC NEUROTRANSMISSION AND PARKINSON'S DISEASE
Parkinson's disease (PD) is one of the most common neurological disorders and affects approximately to 1% of individuals over the age of 60. It consists of a progressive systemic neurodegenerative disorder, in which different brain areas are affected (i.e. locus coeruleus, nucleus basalis of Meynert, dorsal raphe nucleus and the dorsal motor nucleus of the vagus), but it is primarily associated with the loss of pigmented dopaminergic neurons located within the pars compacta of the substantia nigra (SNc) [23] (Fig. 1C) . The initial symptoms of the pathology (pre-motor phase) are poorly specific (i.e. fatigue, depression, constipation, decreased sense of smell and sleep problem), but when the disease advances (motor phase) the associated features and clinical signs are very well-characterized, including resting tremor, rigidity, bradykinesia, and postural instability [24] . Finally, since PD is a neurodegenerative condition, neuronal death continues beyond the motor phase, and it can affect other brain regions, for instance cortical areas, thus patients may then show cognitive dysfunctions and dementia [25] . Unfortunately, when PD motor signs emerge (preclinical phase) around 60-80% of dopaminergic neurons are lost, a fact that points out to the relevance of finding a biomarker of the pathology, especially for early stages of the disease when the motor signs are not apparent [26] .
Glutamatergic neurotransmission within the basal ganglia circuitry is driven by cortical projections to the striatum -caudate and putamen in humans-, the subthalamic nucleus (STN) and the SNc; by thalamic projections to the cortex; and by STN afferents to the internal globus pallidus (GPi) and the substantia nigra pars reticulata (SNr) (Fig. 1 ).
Inhibitory outputs (GABAergic) to the thalamocortical motor circuit are directed from the GPi and the SNr, where it acts to suppress movement. Accordingly, within the basal ganglia two major pathways exist and are referred to as the direct and indirect pathways ( Fig. 1A and B) . Interestingly, these two pathways are classically clasified acording to the dopamine receptor content of the GABAergic striatal medium spiny neurons (MSN) [27, 28] . Thus, the direct pathway, which projects to the GPi/SNr (Fig. 1A) , contains the neuropeptides dynorphin (DYN) and substance P (SP) and it express the dopamine D 1 receptor (D 1 R) (Fig. 2) . On the other hand, the indirect pathway, which projects to the globus pallidus pars externa (GPe) (Fig. 1B) , contains the neuropeptide enkephaline (ENK) and express the dopamine D 2 receptor (D 2 R) (Fig. 2) . Regarding the normal functioning (non-pathological) of these structures, dopaminergic neurons from the SNc release dopamine into the putamen, which activates the direct pathway and inhibits the indirect pathway, and this results in a net inhibition of the GPi/SNr. Overall, this potentiates thalamocortical activity, which facilitates movements (Fig. 2) , cognitive and behavioural outputs. Conversely, in PD, because of the loss of dopaminergic neurons in the SNc, striatal dopamine is reduced and the inhibition of the GPi/SNr decreases (Fig.   1C ). As a consequence, an increment of the GABAergic activity coming from GPi and SNr, the output nuclei of the basal ganglia (Fig. 1C) , is observed and ends in both a reduction of the excitability of thalamic neurons and an alteration of their firing pattern [29, 30] . On the other hand, the glutamatergic activity of the subthalamic projection neurons and the corticostriatal pathway is highly increased. Importantly, this last fact has lead to some interventional PD therapies aimed to drastically reduce this increased glutamatergic activity of the STN, for instance surgical ablation and functional inactivation through deep brain stimulation [31, 32] . However, all surgical procedures have associated risks and surgery is not suitable for everyone (typically only for advanced PD refractory to pharmacotherapy). Therefore, common PD management is still mainly achieved by means of pharmacological treatments (i.e. L-DOPA), and given the tight interconnection between dopaminergic and glutamatergic neurotransmission established in the basal ganglia both in normal and in pathological conditions, the inclusion of other drugs (i.e. mGlu 5 blockers) targeting these systems is now under study and it is precisely the focus of this review. mGlu 5 receptors are expressed throughout the whole basal ganglia, thus they can be found in the striatum (caudate nucleus and putamen), the globus pallidus, the substantia nigra, and the subthalamic nucleus (Fig. 2) [33] . Therefore, mGlu5 receptors may finetune the basal ganglia function by modulating virtually all synaptic contacts present in this group of interconnected subcortical nuclei. For instance, mGlu5 receptors modulate corticostriatal excitatory inputs to the basal ganglia, since they are located both in D 1 Rand D 2 R-containing striatal MSNs (Fig. 2) , although because of this dichotomy in its striatal distribution it is difficult to predict the net effect of mGlu 5 receptor activation/inhibition on the transmission of the direct and indirect pathways. In addition, mGlu5 receptors would modulate transmission through the direct (striatonigral) pathway because they are located in GPi and SNr neurons. Thus, it has been reported that receptor activation produced disinhibition of nigral output neurons by decreasing GABAergic inhibitory transmission [34] . Finally, mGlu5 receptors would also modulate transmission through the indirect pathway by its location at the striatopallidal, pallidosubthalamic and subthalamonigral synapses (Fig. 2) (for review see [33] ).
Collectively, these studies point out to a scenario in which mGlu5 receptor targeting within the basal ganglia will take place at different sites of action according to receptor's distribution, a fact that would potentially enhance the pharmacotherapy based on this type of receptors. Accordingly, it is feasible that the net effect of mGlu 5 receptor antagonists on basal ganglia motor function results from the overall receptor targeting at several different sites including the striatum, STN, and SNr neurons [33] . As described early, the striatum, the input nucleus of the basal ganglia [58] , receives dopaminergic and glutamatergic afferents that converge in the dendritic spines of MSNs (for review see [59] ) (Fig. 3) . Thus, glutamatergic synapses are located at the head, while the dopaminergic afferents are usually located at the neck, of dendritic spines (Fig. 3) . As a consequence, dopamine plays a major modulatory role into the excitatory effects of glutamate in the dendritic spines [60] . Importantly, in addition to dopamine and glutamate, the neuromodulator adenosine also plays a key role in the function of striatal GABAergic efferent neurons [61] . Interestingly, adenosine A 2A receptors (A 2A Rs) are highly concentrated in the striatum, where by means of ultrastructural studies have been located at the dendritic spines of indirect pathway MSNs (i.e. the striatopallidal neurons), especially in the vicinity of glutamatergic synapses [62, 63] , and thus presenting a very similar localization to that described for mGlu 5 receptors [14] ( Fig. 3) . In fact, it has been reported that A 2A Rs functionally interact with mGlu 5 receptors to modulate several downstream mGlu 5 receptor-mediated effects (for review see [64] Overall, all this data provide a rationale for using A 2A R and mGlu 5 receptor antagonists in PD [81, 82] . Furthermore, these non-dopaminergic-based PD therapies may also offer some advantages over dopamine medications, for instance by reducing side effects [83] .
M MO OL LE EC CU UL
From the different promising PD treatments based on the indirect modulation of dopaminergic neurotransmission (for review see [83] ), the use of mGlu 5 receptor blockers has recently received considerable attention by the scientific community. Thus, preclinical data suggested that mGlu 5 receptor blockers might not only be useful in PD treatment by potentiating the benefit of dopamine-based therapies but also by allowing drug dose lowering and by preventing LID development, which has precisely been associated to an increase of striatal glutamatergic neurotransmission [84] . Indeed, the use of PD animal models in preclinical studies has proved to be valuable experimental tools to assess the efficacy of mGlu 5 receptor-based drugs on both reversing motor symptoms and slowing the associated progressive neurodegeneration. Genetic PD animal models based on specific mutations of genes observed in PD familial cases (e.g.
alterations in parkin, α-synuclein, leucine-rich repeat kinase 2 (LRRK2), phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1) and Parkinson diseaseautosomal recessive, early onset-7 (PARK7)) [85] have been shown to be useful for the study of the pathogenesis of familial PD, although since these animal models do not recreate some characteristics of the human disease (e.g. severe motor deficits, lack of dopaminergic neurons degeneration, etc.) they are experimentally restricted to disease associated molecular and cellular studies and often inadequate to pharmacotherapy studies [86] . Accordingly, the preclinical evaluation of mGlu 5 receptor-based drugs have largely relied on pharmacological and toxin-based animal models of PD because these last models often replicate specific pathogenic events and behavioral outcomes of PD. The neurotoxic PD animal models based on systemic or intracerebral administration of compounds that produce both reversible (i.e. haloperidol and reserpine) and irreversible (i.e. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP),
6-hydroxydopamine (6-OHDA), paraquat and rotenone) parkinsonian effects have been effectively used in PD pharmacotherapy studies. Indeed, since the irreversible toxinbased models of PD recapitulate the morphological aspects of the disease (i.e.
dopaminergic system degeneration), and also produce a PD-related pathology and symptomatology, they constitute golden standards models in the study of the diseasemodifying potential of the mGlu5 receptor-based drugs.
The 6-OHDA is a classic and widespread toxin-based animal model of PD [87] that has been successfully used in the study of the function of the mGlu 5 receptor in PD. Partial bilateral 6-OHDA lesions cause akinetic deficits in reaction time tasks, thus recreating a parkinsonian effect of the earlier stages of the disease. Interestingly, it was demonstrated that the chronic instead the acute treatment with 2-methyl-6-(phenylethynyl)-pyridine (MPEP), a mGlu 5 receptor antagonist, reversed these akinetic deficits [88, 89] , therefore suggesting that MPEP treatment might alleviate PDassociated motor executive deficits in an operant task. Also, the effects of MPEP on parkinsonian cognitive deficits has been studied and thus demonstrated that MPEP, either acutely or subchronically, antagonized the visuo-spatial discrimination deficit induced by bilateral 6-OHDA lesion of the striatum [90] . Moreover, in partially lesioned rats chronic systemic MPEP treatment was shown to be neuroprotective and to reverse the abnormal firing activity of dopaminergic neurons [91] . Interestingly, in addition to the MPEP-mediated cognitive and behavioural effects, the same treatment also increased contralateral turning induced by L-DOPA in mice bearing unilateral 6-OHDA lesion [90] , thus confirming the therapeutic potential of mGlu 5 receptor blockade on motor symptoms produced by reduced striatal dopaminergic transmission (for review see [92] ). On the other hand, the MPTP animal model of PD, mainly used in nonhuman primates and mice (rats are resistant to MPTP) [93] , also seed some light about the potential therapeutic usage of mGlu 5 receptor antagonists in PD. Interestingly, an upregulation of mGlu 5 receptors in the posterior putamen and pallidum of MPTPtreated monkeys has been associated with LID development in this PD animal model [94] , thus also supporting that mGlu 5 receptor blockade might alleviate LIDs. Indeed, reduction of glutamatergic neurotransmission by selective mGlu 5 receptor noncompetitive antagonists, either MPEP or 3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine (MTEP), has been shown to improve locomotion and alleviate LID in PD animal models [95] [96] [97] . Needless to say, apart from the mGlu 5 receptor blockers we revise here, other agents able to reduce glutamate neurotransmission might indeed become valued drugs to PD therapy. Thus, amantadine, an NMDA-receptor antagonist, has demonstrated efficacy in reducing LID both in animal models and PD patients, although its short-term efficacy, together with its neurological side effects, has precluded its clinical use [98, 99] . Overall, the antidyskinetic efficacy of selective mGlu 5 receptor antagonists supports the hypothesis that abnormally increased glutamatergic neurotransmission is involved in LID and points to the mGlu 5 receptor as a potential therapeutic target for the treatment of LID. Collectively, these preclinical studies supported the use of mGlu 5 receptor antagonists as anti-parkinsonian drugs.
C CL LI IN NI IC CA AL L E EV VA AL LU UA AT TI IO ON N O OF F m mG Gl lu u 5 5 R RE EC CE EP PT TO OR R B BL LO OC CK KE ER RS S I IN N P PD D
In clinics, the therapeutic potential of mGlu 5 receptors has been progressively explored, mainly for both peripheral and central nervous disorders ranging from psychiatric, neurological to neuromuscular illnesses [100] . Indeed, the usefulness of mGlu 5 receptor blockers is actually being challenged not only in neurodegenerative disorders as PD but also in the treatment of addiction, pain, schizophrenia or anxiety disorders [101, 102] .
Regarding the management of PD, these kind of compounds has been mainly proposed as adjuvant drugs to PD L-DOPA therapy, not only as a feasible option assisting the symptomatic PD treatment but mostly for the alleviation of LID [92] . Indeed, several Nevertheless, it is also true that still few clinical trials assessing the efficacy of these compounds in human beings have been carried out (Table 1) or are ongoing (Table 2) .
From this plethora of compounds, it is worth mentioning the drug (3aR,4S,7aR)- (Table 1) . Importantly, only the complete results of two of the clinical trials have been published [108] , while the others just presented in international congresses [109, 110] . The primary objectives of these trials were to assess the antidyskinetic efficacy, as well as the safety and tolerability, of multiple AFQ056 doses on moderate to severe LID in PD patients. Interestingly, a low number (less than 300) of patients have been currently included in these clinical trials, whose main characteristics are shown in table 3. In brief, the mean age (SD) of the patients in these trials was 64.5 (8.6) years old and approximately 53% were men. On the other hand, for the inclusion of these patients in the named clinical trials they had to have received L-DOPA for at least 3 years and were required to remain on stable L-DOPA therapy for the duration of these studies. Moreover, these patients were also required to have moderate to severe LID. Finally, it is also worth to mention that these studies were short in time (from two to twelve weeks) ( Table 1) .
Regarding the dose of AFQ056 used, in two clinical trials it was steadily increased every 4 days from 25 mg to a maximum dose of 150 mg twice a day during a period of 16 days (CAFQ056A2203 and CAFQ056A2206), and just in one of them patients were also down-titrated (50 mg twice a day) from day 17 to day 20 mg (CAFQ056A2206) [108] . Thus, in the studies carried out by Berg et al. However, several methodological problems arise from using these PD scales to measure dyskinesia, which have been well described elsewhere [111] . For instance, as mentioned above, the short duration of these clinical trials, or importantly the lack of a fully validation of some scales (i.e. LFADLDS and the modified AIMS version), which may have limited the ability to detect changes in functional impairment among the study population. Therefore, although AFQ056 showed some antidyskinetic efficacy when measuring dyskinesia with the former scales, the clinical relevance of these results can be considered is vague and difficult to interpret (Table 4) . Thus, no significant effects were seen on UPDRS-III in any study. Similarly, only in the Stocchi et al. study (CAFQ606A2208) [109] there was a dose-response relationship in the primary outcome (change from baseline at week 12 on the modified AIMS) with the 100 mg twice-a-day dose (Table 5) . And again, no significant changes were observed in any case on the secondary outcomes, such as Parkinson Disease Dyskinesia Scale (PDYS-26), Clinical
Global Impression of Change (CGIC) and UPDRS-III.
With respect to possible adverse effects of the studied drug, summing the total number of adverse events observed in the abovementioned four clinical trials, they were found in 128 patients out of 169 (75.7%) treated with AFQ056 and in 70 patients out of 100 (70%) treated with placebo. The reported adverse events were typically mild to moderate in severity and included nervous system, gastrointestinal and psychiatric disorders (Table 6 ). Dizziness (15%) and dyskinesia (7%), followed by nausea (4%) and hallucinations (4%) were the most common adverse events in patients treated with AFQ056 (Table 6 ) while dyskinesia (18%) and nausea (8%) were the most frequent in patients treated with placebo. Importantly, twenty patients out of 169 patients treated with AFQ056 (11.8%) discontinued the experimental drug as a consequence of adverse events appearance. Concretely, in the two clinical trials carried out by Berg et al.
(CAFQ056A2203 and CAFQ056A2206) [108] , the most common severe adverse event was worsening of dyskinesia, which arose after stopping treatment. Thus, five severe adverse events were observed in the study 1 of Berg et al. (CAFQ056A2203), from which four occurred in the AFQ056 group and were considered serious (two patients experienced worsening of dyskinesia, one patient developed hyperkinesia, and one patient had two serious events, such as a fall and rhabdomyolisis). Similarly, in the study 2 of Berg et al. (CAFQ056A2206) there were four severe adverse events in the AFQ056 group and three in the placebo group, from which two in each group were considered serious adverse events. Noteworthy, and related to the results obtained in the study 1, two serious adverse events in AFQ056-treated patients were suspected to be related to the study medication. In particular, one patient developed psychosis, which required discontinuation of treatment, while the other patient had dyskinesia worsening.
In the Stocchi et al. study (CAFQ606A2208) [109] , adverse events were reported by 65.1% of the placebo group patients and by 75% of the medication study group of patients daily-treated with 100 mg of AFQ056. Importantly, adverse events requiring dosing modification or interruption increased progressively from 4.8% in the placebo group to 22.7% in the AFQ056 (200 mg/daily) group. Finally, serious adverse events were observed in 9.5% of the placebo group and in 11.4% of AFQ056 200 mg/dailytreated patients. In such way, psychosis and psychotic disorders-related adverse events increased gradually from 1.6% in the placebo group to 22.7% in the AFQ056 (200 mg/daily) group of patients.
To finish with the AFQ056 characterization, it is needed to say that scarce information is available about AFQ056 pharmacokinetics. Thus, it has been shown that the steady state plasma concentration-time profiles of AFQ056 alone or when co-administered with L-DOPA/carbidopa are similar, thus indicating that the co-administration of a L-DOPA/carbidopa combination has no relevant effects on AFQ056 pharmacokinetics [112] . On the other hand, the pharmacokinetics of AFQ056 has been shown to be altered in subjects with renal impairmen: the AUC (area under the plasma concentration-time curve) of AFQ506 is increased in patients with mild, moderate and severe renal impairment, compared with healthy control subjects (Novartis Clinical Trial Database: CAFQ056A2124, http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult= 6624). Finally, no data is available assessing the pharmacokinetics of AFQ056 in subjects with hepatic impairment, although some studies are now ongoing.
In summary, despite the promising results observed in preclinical studies, today there are few clinical trials, including a small number of PD patients, which have assessed the efficacy and safety of mGlu 5 receptor antagonists in humans. The preliminary results of these studies suggest some antidyskinetic efficacy in PD patients with LID, but the clinical relevance of the reported outcomes is uncertain and difficult to interpret due to the methodological problems associated with the measuring-scales used. On the other hand, adverse events (from mild to moderate in severity) associated with these drugs have been shown to be common (mainly gastrointestinal and neuropsychiatric disorders), and together with the fact that there is still lacking consistent pharmacokinetic data to establish the optimum drug-treatment, it is obvious that more research is needed to properly evaluate the therapeutic potential of this new group of drugs in the treatment of PD.
C CO ON NC CL LU UD DI IN NG G R RE EM MA AR RK KS S
The current pharmacological approach dealing with parkinsonian symptoms entirely relies on dopamine replacement therapy either with L-DOPA or with D 2 R agonists.
However, long-term dopamine-based therapies promote the development of intolerable motor adverse effects like dyskinesia and motor fluctuations. As a consequence, a lot of effort has been focused on the search for new non-dopaminergic-based drugs to be incorporated into PD therapeutic arsenal. Indeed, mGlu 5 receptor blockers constitute one of the most attractive non-dopaminergic classes of drugs for PD management in general and for the LID treatment in particular. Accordingly, these drugs would have antiparkinsonian effects by reducing the excitatory drive occurring in the enkephalin MSN of the overactive parkinsonian basal ganglia, a phenomenon that might be related to the physical interaction (oligomerization) between D 2 R and mGlu 5 receptor in the MSN glutamatergic synapses.
A AC CK KN NO OW WL LE ED DG GM ME EN NT TS S
This work was supported by grants SAF2011-24779 and Consolider-Ingenio CSD2008- there is a loss of SNc dopaminergic neurons which results in a reduction in the direct pathway-mediated inhibitory transmission and an increase in the indirect pathway-mediated inhibitory transmission, therefore resulting in an increased excitation of the output nuclei via the STN. Overall, this increase in the excitation of the SNr-GPi complex implies a concomitant increase of GABAergic tone at the thalamus which ends with a reduction of the excitation of cortical motor areas. Adapted from [92] and [113] . NMDAR: NMDA receptor. Adapted from [115] . 
R RE EF FE ER RE EN NC CE ES S

